Karaferic A, Jovanovic D, Jelic S
Clinic for Medical Oncology, Institute of Oncology and Radiology of Serbia, Belgrade, Serbia.
J BUON. 2009 Oct-Dec;14(4):635-9.
To examine the expression of the membrane markers of estrogen (ER) and progesterone receptors (PR), CA-125, CA 19-9 and HER2/neu in ovarian cancer tissues.
Fifty-four samples of ovarian cancer tissues originating from 55 patients were examined by immunohistochemistry. Forty-three had serous papillary ovarian cancer, 9 of which were grade I, 12 grade II and 2 grade III. Twelve patients had a classic mucinous ovarian cancer, 5 of which were grade I, 4 grade II and 0 grade III.
Out of 43 patients with serous ovarian cancer, 7 expressed both steroid receptors, 22 had only one (10 ER and 12 PR), while 14 were negative. Only 2/12 patients with classic mucinous ovarian cancer expressed of both receptors. CA-125 was expressed in 37/43 patients with serous ovarian cancer and in 4/12 patients with classic mucinous ovarian cancer. CA 19-9 was expressed in 3/43 patients with serous ovarian cancer, and coexpressed with CA-125 in 2/3 patients. In patients with classic mucinous ovarian cancer, 4/12 had expression of CA 19-9 without coexpression with CA-125. HER2/neu positivity (3+) was proven in only one case with classic mucinous ovarian cancer, and any other expression (1+) in 7 additional patients (1 mucinous and 6 serous ovarian cancers).
Positive HER2/neu expression in the cells of ovarian cancer is very rare and HER2/neu overexpression is even rarer. Expression of ER and PR does not depend on tumor grade and/or at least not in grade I and II. Positive CA 19-9 expression may be present not only in cases of classic mucinous ovarian cancer but also in typical serous ovarian cancer. However, in the classic mucinous ovarian cancer, CA-125 may be expressed, though in relatively low percentage.
检测雌激素（ER）和孕激素受体（PR）、CA - 125、CA 19 - 9及HER2/neu在卵巢癌组织中的膜标志物表达情况。
采用免疫组织化学法检测55例患者的54份卵巢癌组织样本。其中43例为浆液性乳头状卵巢癌，Ⅰ级9例，Ⅱ级12例，Ⅲ级2例。12例为经典黏液性卵巢癌，Ⅰ级5例，Ⅱ级4例，Ⅲ级0例。
43例浆液性卵巢癌患者中，7例同时表达两种甾体受体，22例仅表达一种（10例ER和12例PR），14例为阴性。12例经典黏液性卵巢癌患者中仅2例同时表达两种受体。CA - 125在43例浆液性卵巢癌患者中的37例以及12例经典黏液性卵巢癌患者中的4例表达。CA 19 - 9在43例浆液性卵巢癌患者中的3例表达，其中2例与CA - 125共表达。在经典黏液性卵巢癌患者中，12例中有4例表达CA 19 - 9且不与CA - 125共表达。仅1例经典黏液性卵巢癌患者HER2/neu呈阳性（3+），另有7例患者（1例黏液性和6例浆液性卵巢癌）呈其他表达（1+）。
卵巢癌细胞中HER2/neu阳性表达非常罕见，HER2/neu过表达更为罕见。ER和PR的表达不依赖于肿瘤分级，至少在Ⅰ级和Ⅱ级中如此。CA 19 - 9阳性表达不仅可能出现在经典黏液性卵巢癌病例中，也可能出现在典型浆液性卵巢癌中。然而，在经典黏液性卵巢癌中，CA - 125可能表达，尽管比例相对较低。
